Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion description "[Studies have shown that mutations in the epidermal growth factor receptor (EGFR) tyrosine kinase domain are associated with response of lung cancer to gefitinib (Iressa, AstraZeneca Corp., Shanghai, China).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion evidence source_evidence_literature NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion SIO_000772 15958609 NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion wasDerivedFrom befree-2016 NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_assertion wasGeneratedBy ECO_0000203 NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.
- befree-2016 importedOn "2016-02-19" NP499751.RAO2Gn8jIpTpoM1Qp2SWlXEQJ0NKoi90tk6jMCZKpd_Pw130_provenance.